Activity of idelalisib in high-risk follicular lymphoma with early relapse following front-line immunochemotherapy
Preliminary results of a phase II, open-label study of venetoclax monotherapy in patients with CLL relapsed after or refractory to ibrutinib or idelalisib therapy
Idelalisib plus bendamustine and rituximab (BR) is superior to BR alone in patients with relapsed/refractory CLL: Results of a phase III randomized double-blind placebo-controlled study
Characterization of atrial fibrillation and bleeding risk factors in patients with CLL: A population-based retrospective cohort study of administrative medical claims data in the U.S.
Idelalisib given front-line for the treatment of CLL results in frequent and severe immune-mediated toxicities
Idelalisib monotherapy and durable responses in patients with relapsed or refractory marginal zone lymphoma
Afatinib versus gefitinib as first-line treatment for patients with advanced non-small cell lung cancer harboring activating EGFR mutations: LUX-Lung 7
New Targeted Agents Demonstrate Greater Efficacy and Tolerability in the Treatment of HER2-positive Breast Cancer